New hope for toddlers with rare brain tumors: targeted drug entrectinib tested

NCT ID NCT06528691

Recruiting now Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug entrectinib in children under 3 with certain brain tumors (NTRK or ROS1 gene fusions). The goal is to see if the drug can shrink tumors and delay the need for chemotherapy. About 52 children will take entrectinib by mouth, and doctors will monitor tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Entrectinib (Rozlytrek)
What this could lead to: If successful, this could offer a targeted, chemotherapy-sparing option for young children with these rare brain tumors, potentially improving outcomes and reducing side effects.
What could go wrong: This is a small, early-phase trial (52 children) with no control group. The drug may not work for all tumor types, and side effects are possible. Long-term benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CNS TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer central nervous system neoplasm glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CNS TUMOR HIGH GRADE GLIOMA

Contacts and locations

Locations

GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer)
RECRUITING

São Paulo, 04039-001, Brazil
Hospital Santa Marcelina
RECRUITING

São Paulo, 08270-070, Brazil
Hospital de Câncer de Barretos
RECRUITING

Barretos, São Paulo, 14784400, Brazil
Instituto Nacional de Enfermedades Neoplásicas
RECRUITING

Lima, Peru
King Hussein Cancer Center
RECRUITING

Amman, 11941, Jordan
St. Jude Children's Research Hospital
RECRUITING

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.